Search hospitals > Massachusetts > Boston
Boston University School of Medicine
Claim this profileBoston, Massachusetts 02118
Global Leader in High Blood Pressure
Global Leader in Pulmonary Hypertension
Conducts research for Systemic Scleroderma
Conducts research for Scleroderma
Conducts research for Alzheimer's Disease
124 reported clinical trials
3 medical researchers
Summary
Boston University School of Medicine is a medical facility located in Boston, Massachusetts. This center is recognized for care of High Blood Pressure, Pulmonary Hypertension, Systemic Scleroderma, Scleroderma, Alzheimer's Disease and other specialties. Boston University School of Medicine is involved with conducting 124 clinical trials across 137 conditions. There are 3 research doctors associated with this hospital, such as Marcin Trojanowski, MD, Monica Crespo-Bosque, and Ann M Rasmusson, MD.Top PIs
Marcin Trojanowski, MDBoston University5 years of reported clinical research
Studies Systemic Scleroderma
Studies Scleroderma
2 reported clinical trials
3 drugs studied
Monica Crespo-BosqueBoston University School of Medicine3 years of reported clinical research
Studies Systemic Lupus Erythematosus
1 reported clinical trial
2 drugs studied
Ann M Rasmusson, MDBoston University School of Medicine2 years of reported clinical research
Studies Post-Traumatic Stress Disorder
Studies Traumatic Stress Disorders
1 reported clinical trial
3 drugs studied
Clinical Trials running at Boston University School of Medicine
Scleroderma
Systemic Sclerosis
Amyloidosis
Systemic Scleroderma
Multiple Sclerosis
Cardiomyopathy
Polyarteritis Nodosa
Post-Traumatic Stress Disorder
Interstitial Lung Disease
Pathology
HZN-825
for Systemic Sclerosis
This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Baseline (Day 1) Visit. Approximately 300 participants who meet the trial eligibility criteria will be randomized on Day 1 in a 1:1:1 ratio to receive HZN-825 300 mg QD, HZN-825 300 mg BID or placebo for 52 weeks. The trial will include up to a 42-day Screening Period and a 52-week Double-blind Treatment Period. Participants will take their first dose of trial drug at the clinic and will participate in trial visits at Week 4 and every 6 weeks thereafter until Week 52. All participants who complete the Double-blind Treatment Period (Week 52) will be eligible to enter a 52-week extension trial (HZNP-HZN-825-302, NCT05626751). Participants not entering the extension trial will participate in a Safety Follow-up Visit 4 weeks after the last dose of trial drug.
Recruiting0 awards Phase 26 criteria
PRA023
for Systemic Sclerosis-Associated ILD
This trial tests a new medication called tulisokibart on people with a lung disease called SSc-ILD. The goal is to see if it is safe and helps improve their condition.
Recruiting0 awards Phase 2
Oral Ifetroban
for Scleroderma
This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Recruiting0 awards Phase 22 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Boston University School of Medicine?
Boston University School of Medicine is a medical facility located in Boston, Massachusetts. This center is recognized for care of High Blood Pressure, Pulmonary Hypertension, Systemic Scleroderma, Scleroderma, Alzheimer's Disease and other specialties. Boston University School of Medicine is involved with conducting 124 clinical trials across 137 conditions. There are 3 research doctors associated with this hospital, such as Marcin Trojanowski, MD, Monica Crespo-Bosque, and Ann M Rasmusson, MD.